Free Trial
NASDAQ:SYRE

Spyre Therapeutics Q3 2024 Earnings Report

Spyre Therapeutics logo
$12.71 +0.20 (+1.60%)
Closing price 05/7/2025 04:00 PM Eastern
Extended Trading
$12.68 -0.04 (-0.28%)
As of 05/7/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics EPS Results

Actual EPS
-$1.36
Consensus EPS
-$0.80
Beat/Miss
Missed by -$0.56
One Year Ago EPS
N/A

Spyre Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyre Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Spyre Therapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Spyre Therapeutics Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Spyre Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email.

About Spyre Therapeutics

Spyre Therapeutics (NASDAQ:SYRE), a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

View Spyre Therapeutics Profile

More Earnings Resources from MarketBeat